comprehensive -WSS

comprehensive

author：Wikipedia 2025-10-01 21:40:55 - browse：64

light shines behind Pfizer CEO Albert Bourla as he attends a ceremony in Greece — Pfizer CEO Albert Bourla Giannis Papanikos/AP

Pfizer has a big problem. The drug giant hopes that new drugs to treat cancer are the solution.

Shares in the drugmaker fell 44% last year, and it now has a market capitalization of only $150 billion — a quarter that of Eli Lilly and half that of longtime rival Merck. In March of last year the company announced that it would spend $43 billion to buy Seagen, a maker of a hot category of oncology medicines called antibody-drug conjugates. Pfizer’s shares have slumped another 9% so far this year. On Thursday, executives are holding an investor briefing to try to convince shareholders that its bet will pay off.

In an interview with STAT, Pfizer CEO Albert Bourla was insistent that the deal’s potential is being missed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Group opposing PBM reform sets lobbying record

WSS

Can U.S. cancer drug shortages be fixed?

Group opposing PBM reform sets lobbying record

Sanders adds drug shortage policies to pandemic preparedness bill

Trump to be booked at notorious Fulton County Jail at center of DOJ probe

California store owner shot dead in dispute over displaying Pride flag: Police

Trump to be booked at notorious Fulton County Jail at center of DOJ probe

explore

comprehensive

focus

Continuity nursing helped my family in our darkest PICU moments

Key House panel plots a new health care package

Medical leaders decry Supreme Court decision on affirmative action

In early work, researchers turn to CRISPR to treat Alzheimer's

Sports medicine is finally prioritizing gender equality

Health officials lay out plans to cope with respiratory virus season

Tori Bowie and the unacceptable rates of Black maternal death

As digital health tech proliferates, a new institute aims to cut through hype

Affirmative action in medical school literally saved lives

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

explore

Vivek Ramaswamy made waves in the debate, much as in biotech

As digital health tech proliferates, a new institute aims to cut through hype

At Orexo, a ‘turning point’ for everything but digital health

PBMs are inflating the cost of generic drugs. They must be reined in

Biden tests positive for Covid

Why hospitals are withdrawing from US News rankings

hotspot

focus

Wikipedia

Wikipedia